Loading...

BeOne Medicines Ltd.

ONCNASDAQ
Healthcare
Medical - Pharmaceuticals
$244.32
$-0.84(-0.34%)

BeOne Medicines Ltd. (ONC) Stock Overview

Explore BeOne Medicines Ltd.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 64.2/100

Key Financials

Market Cap24.2B
P/E Ratio-66.15
EPS (TTM)$-3.63
ROE-0.12%
Fundamental Analysis

AI Price Forecasts

1 Week$263.73
1 Month$278.26
3 Months$213.94
1 Year TargetN/A

ONC Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of BeOne Medicines Ltd. (ONC) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of N/A.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -66.15 and a market capitalization of 24.2B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Revenue Growth
54.96%
54.96%
Profit Growth
$-0.28
26.87%
EPS Growth
$-0.28
27.69%
Operating Margin
-7.08%
52.95%
ROE
-11.51%
26.87%
Dividend Yield
0.00%

Analyst Recommendations

Strong Buy
0
Buy
1
Hold
0
Sell
0
Strong Sell
0

Price Targets

Low$259.00
Average$303.50
High$348.00

Company Profile

BeOne Medicines, formerly known as BeiGene, is a global oncology company focused on discovering, developing, and commercializing innovative cancer therapies. Founded in 2010 and headquartered in Cambridge, Massachusetts—with operations spanning over 45 countries across six continents—the company rebranded as BeOne in late 2024 and redomiciled to Basel, Switzerland in 2025. BeOne has established itself as a leader in immuno-oncology and targeted therapies, with key assets including Tevimbra (tislelizumab), a PD-1 monoclonal antibody approved for multiple cancer indications globally, and Brukinsa (zanubrutinib), a Bruton's tyrosine kinase (BTK) inhibitor that surpassed $1.3 billion in annual sales and is approved in major markets such as the U.S., Europe, and China. The company’s strategy combines internal R&D with the development of assets sourced from external partnerships, driving a robust pipeline across hematologic malignancies and solid tumors.

CEO

John V. Oyler

Employees

11,000

Headquarters

94 Solaris Avenue, Camana Bay

Founded

2016

Frequently Asked Questions

;